The largest database of trusted experimental protocols

5 protocols using anti cd3 clone 2c11

1

Differentiation of Th1 and Th17 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+ T cells were purified from spleens of naïve DBA/1 mice by positive selection using microbeads against CD4 (Miltenyi Biotec) following the protocol provided by the manufacturer. Then, the purified naïve CD4+ T cells were seeded at 2 × 106 per well into 96-well U-bottom microplates with RPMI 1640 medium (Hyclone) supplemented with 10% fetal bovine serum (Hyclone, Carlsbad, CA), 100 units/ml penicillin, and 100 μg of streptomycin (all from Invitrogen-Gibco). Th1 differentiation was driven by the of naïve CD4+ T cells with 1 μg/ml plate-bound anti-CD3 (clone 2C11, eBioscience), 1 μg/ml soluble anti-CD28 (clone PV1.17, eBioscience), 10 ng/ml IL-12 (PeproTech), 5 ng/ml IL-2 (PeproTech), and 2 μg/ml anti-IL-4 antibody (clone 11B11, eBioscience). Th17 differentiation was driven by the stimulation of naïve CD4+ T cells with 1 μg/ml plate-bound anti-CD3, 1 μg/ml soluble anti-CD28, 50 ng/ml IL-6 (PeproTech), 10 ng/ml TGF-β1 (PeproTech), 2 μg/ml anti-IFN-γ antibody (clone R4-6A2, eBioscience) and 2 μg/ml anti-IL-4 antibody. DXM was used at the dose indicated at the beginning of the Induction. Cells were harvested on day 4 of DXM treatment and analyzed for intracellular cytokines while culture supernatants were examined for cytokine levels by ELISA assay.
+ Open protocol
+ Expand
2

Isolation and activation of T cell subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+CD25- and CD8+ T cells were isolated from spleen and lymph nodes to ≥90% purity by magnetic bead negative selection (Miltenyi Biotec). Cells were cultured in RPMI 1640 (MediaTech) supplemented with 10% FBS (Gemini BioProducts), penicillin-streptomycin (Gibco), L-glutamine (Gibco), and 50 µM β-ME (Sigma). Where indicated, cells were maintained in a quiescent, viable state using 10 ng/ml IL-7 (eBioscience). Alternatively, cells were stimulated on plates coated with 10 µg/ml anti-CD3 (clone 2C11) and 10 µg/ml anti-CD28 (both eBioscience) in the presence of 20 ng/ml IL-2 (Novartis), with a starting density of 0.5–1.5×106 cells/ml. Cell concentration and size were measured using a Z2 particle counter (Coulter Corp.). Where indicated cells were activated in the presence of 2-deoxyglucose (Sigma) or rotenone (Seahorse Bioscience).
+ Open protocol
+ Expand
3

Identification and Quantification of ILC2 in BALF

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were analyzed by flow cytometry following staining with live/dead aqua dyes (Live/Dead fixable aqua dead cell stain kit, Invitrogen, 1/1000) and antibodies specific for the following markers: anti-TCRβ (clone H57-597, 5.0 μg/ml) from BioLegend; anti-CD45R/B220 (clone RA3-6B2, 1.0 μg/ml), anti-CD2 (clone RM2-5, 0.8 μg/ml), anti-CD25 (clone PC61, 1.0 μg/ml), anti-CD90.2 (clone 53-2.1, 2.5 μg/ml), and anti-CD11b (clone M1/70, 0.3 μg/ml) antibodies from BD Pharmingen; anti-CD45.2 (clone 104, 0.5 μg/ml) from eBioscience. ILC2 were gated as CD45+, CD2 TCRb B220 CD11b, CD90+ and CD25+ cells in a similar manner to that described by Roediger et al.10 (link). Bronchoalveolar lavage fluid (BALF) cells were additionally labeled using anti-Siglec F (clone E50-2440, 2.0 μg/ml), from BD Pharmingen; anti-Gr-1 (clone RB6-8C5, 0.4 μg/ml), anti-CD8 (clone 53-6.7, 5.0 μg/ml), anti-CD4 (clone GK1.5, 1.0 μg/ml), anti-CD3 (clone 2C11, 1.0 μg/ml) from eBioscience; and anti-CD11c (clone N418, 2.5 μg/ml) from BioLegend.
+ Open protocol
+ Expand
4

Identification and Quantification of ILC2 in BALF

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were analyzed by flow cytometry following staining with live/dead aqua dyes (Live/Dead fixable aqua dead cell stain kit, Invitrogen, 1/1000) and antibodies specific for the following markers: anti-TCRβ (clone H57-597, 5.0 μg/ml) from BioLegend; anti-CD45R/B220 (clone RA3-6B2, 1.0 μg/ml), anti-CD2 (clone RM2-5, 0.8 μg/ml), anti-CD25 (clone PC61, 1.0 μg/ml), anti-CD90.2 (clone 53-2.1, 2.5 μg/ml), and anti-CD11b (clone M1/70, 0.3 μg/ml) antibodies from BD Pharmingen; anti-CD45.2 (clone 104, 0.5 μg/ml) from eBioscience. ILC2 were gated as CD45+, CD2 TCRb B220 CD11b, CD90+ and CD25+ cells in a similar manner to that described by Roediger et al.10 (link). Bronchoalveolar lavage fluid (BALF) cells were additionally labeled using anti-Siglec F (clone E50-2440, 2.0 μg/ml), from BD Pharmingen; anti-Gr-1 (clone RB6-8C5, 0.4 μg/ml), anti-CD8 (clone 53-6.7, 5.0 μg/ml), anti-CD4 (clone GK1.5, 1.0 μg/ml), anti-CD3 (clone 2C11, 1.0 μg/ml) from eBioscience; and anti-CD11c (clone N418, 2.5 μg/ml) from BioLegend.
+ Open protocol
+ Expand
5

Inducing Regulatory T Cells from Naive CD4+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The sorted CD4+CD25Foxp3 (GFP) T cells were stimulated in vitro with plate-bound anti-CD3 (clone 2C11 at 2 µg/ml, eBioscience) plus soluble anti-CD28 (1 µg/ml) in the presence or absence of recombinant TGF-β (5 ng/ml, R&D Systems) and IL-2 (5 ng/ml, PeproTech) for 3–5 days. Conversion of Foxp3+ Treg cells were then analysed by flow cytometry based on the expression of GFP or intracellular staining for Foxp3. In the indicated experiments, cells were cultured in plates coated with PD-1H agonist mam82 (10 µg/ml) after plate-coated with anti-CD3 (1 µg/ml). For the cytokine neutralization experiments, the mAb to IL-4, IL-6, and IFN-γ at 10 µg/ml were added to the wells at the beginning of the cultures. The cultured supernatants were collected at the indicated time points for the cytokine analysis.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!